Drug Approval | June 14, 2022
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Amarex Clinical Research guides its client to phase II of FDA trials
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
Subscribe To Our Newsletter & Stay Updated
